Revolutionizing Dermatology Education
Subscribe:.rss.atom.json.md.m3u.pls
Live Last read · last published · next check
Saves to your Listen queue, to pick up on another day or another device.
The management of hidradenitis suppurativa (HS) is evolving, but many patients still face significant hurdles in achieving optimal outcomes with current therapies. In this episode, "JAK Inhibition and the Future of HS Treatment," expert dermatologists, Hadar Lev-Tov, MD, and Jennifer L. Hsiao, MD discuss: Increasing Awareness: Debunking common myths and misconceptions about HS. Building Trust:…
This is the final installment of our 4-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." In this episode, "Moving into the Non-Steroidal Topical Therapy Age," we dive into the current and emerging landscape of targeted topical therapies for AD patients. Our experts review the latest clinical data, discuss how they are practically integrating…
The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, "Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective," expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss:…
This is the third part of our four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." This episode, "Addressing Patient Concerns Regarding Treatment of Dermatoses Using Steroids," focuses on the importance of patient education and shared decision-making. In this episode, supported by an educational grant from Arcutis, expert dermatologists Mona…
In the second installment of our four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD," we're tackling a topic that's often misunderstood and highly challenging: Topical Steroid Withdrawal (TSW). Supported by an educational grant from Arcutis, this episode, "Topical Steroid Withdrawal – Myths vs Science," features expert dermatologists Dr Mona…
This is the first episode of a four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD," supported by an educational grant from Arcutis. In this episode, "Steroidal vs Non-Steroidal Topicals – Case by Case Discussion," expert dermatologists, Mona Shahriari, MD and James Song, MD, discuss: Appropriate use of topical corticosteroids and targeted…
In this episode, entitled "JAK Inhibition for Treatment of Vitiligo," expert dermatologists, Dr Andrew Alexis, MD, MPH and Dr Erik Domingues, MD, FAAD, discuss the following topics: · Changing the culture of vitiligo care · Diagnosing vitiligo and associated comorbidities · Strategies for managing vitiligo and educating patients about treatment options · Setting patient expectations for the…
This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics: Mechanism of action for…
This is the second episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, is joined by Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford…
This is the sixth episode of our ongoing "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?", featuring Beth Sweney, PA-C discusses the following topics: Challenges in achieving treatment targets in AD Therapeutic inertia and clinical…
